Biotech - Gene Therapy
•108 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (108)
%
| Company | Market Cap | Price |
|---|---|---|
|
Gedeptin is a gene-directed/oncolytic therapy delivered via a viral vector, aligning with Biotech - Gene Therapy.
|
$8.44M |
$0.56
-7.43%
|
|
Viral-based platform indicative of gene/viral therapy approaches (oncolytic virus).
|
$8.21M |
$0.35
|
|
CAR T and viral gene-modified therapies align with gene therapy category (vector-based therapeutic approaches).
|
$6.92M |
$1.56
-0.95%
|
|
Genetic modification of gamma-delta T cells and iPSC-based components suggest a gene therapy-related platform.
|
$6.35M |
$2.10
-7.08%
|
|
PlaCCine is a DNA-based vaccine platform, aligning with Biotech - Gene Therapy.
|
$5.23M |
$5.37
-0.56%
|
|
The company employs gene therapy modality via viral vectors delivering genetic payloads (e.g., IL-15 superagonist) as part of its OV platforms.
|
$4.11M |
$1.55
-1.90%
|
|
CER-T involves genetic modification of T cells, aligning with gene therapy within biotech.
|
$1.28M |
$3.31
-20.24%
|
|
Gene therapy platforms/approaches are part of RGBP's pipeline alongside cell therapies.
|
$703985 |
$0.02
-41.18%
|
Showing page 2 of 2 (108 total stocks)
Loading industry metrics...
Loading comparison data...
